AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2009.LEXINGTON, Mass. -- AMAG AMAG African Microbicides Advocacy Group AMAG Agricultural Machinery Advisory Group Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : AMAG) today announced it will report unaudited consolidated financial results for the third quarter ended September 30, 2009 before the U.S. financial markets open on October 29, 2009. The announcement will be followed by a conference call at 8:30 a.m. ET during which management will discuss the Company's third quarter financial results, development programs, and the recent launch of Feraheme[TM] (ferumoxytol) Injection. To access the conference call via telephone, please dial (877) 412-6083 from the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:30 a.m. ET on October 29, 2009 through midnight November 2, 2009. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The passcode for the live call and the replay is 36056615. The call will be webcast with slides and accessible through the Investors section of the Company's website at www.amagpharma.com. The webcast replay will be available from approximately 11:30 a.m. ET on October 29, 2009 through midnight November 12, 2009. About AMAG Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia Iron Deficiency Anemia Definition Anemia can be caused by iron deficiency, folate deficiency, vitamin B12 deficiency, and other causes. The term iron deficiency anemia means anemia that is due to iron deficiency. and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . AMAG recently received approval from the U.S. Food and Drug Administration to market Feraheme for the treatment of iron deficiency anemia in adult chronic kidney disease Chronic kidney disease (CKD), also know as chronic renal disease, is a progressive loss of renal function over a period of months or years through five stages. Each stage is a progression through an abnormally low and progressively worse glomerular filtration rate, which is patients. For additional company and product information, please visit www.amagpharma.com. Feraheme[TM] is a trademark of AMAG Pharmaceuticals, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion